2/26
07:00 am
avir
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
Neutral
Report
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
2/24
07:00 am
avir
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
Low
Report
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
1/23
05:06 am
avir
Atea Pharmaceuticals (NASDAQ:AVIR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
Atea Pharmaceuticals (NASDAQ:AVIR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/13
01:56 pm
avir
Bullish Atea Pharmaceuticals Insiders Loaded Up On US$5.40m Of Stock [Yahoo! Finance]
Low
Report
Bullish Atea Pharmaceuticals Insiders Loaded Up On US$5.40m Of Stock [Yahoo! Finance]
1/8
07:11 am
avir
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/8
07:00 am
avir
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
1/6
07:00 am
avir
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Neutral
Report
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/23
05:54 am
avir
Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 [Seeking Alpha]
Medium
Report
Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 [Seeking Alpha]
12/22
08:05 am
avir
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus [Yahoo! Finance]
Low
Report
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus [Yahoo! Finance]
12/22
07:00 am
avir
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Low
Report
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
12/2
06:16 am
avir
Atea Pharmaceuticals (NASDAQ:AVIR) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Low
Report
Atea Pharmaceuticals (NASDAQ:AVIR) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.